JW Life Science

JW Life Science FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of JW Life Science (234080.KS) as of Oct 16, 2026 is 94.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.81 % — a change of 3.20% (higher).

FCF Conversion

94.75 %

YoY

3.20%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of JW Life Science is 2025 94.75 % . FCF Conversion Rate (FCF/EBITDA) of JW Life Science was 2024 91.81 % . It decreases by 3.20% higher compared to the previous year.

The JW Life Science FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
164.89 KRW
Jan 1, 2019
73.77 KRW
Jan 1, 2020
182.75 KRW
Jan 1, 2021
86.64 KRW
Jan 1, 2022
39.00 KRW
Jan 1, 2023
104.13 KRW
Jan 1, 2024
91.81 KRW
Jan 1, 2025
94.75 KRW
The JW Life Science FCF Conversion history
YEARFCF ConversionYoY
94.75 %+3.20%
91.81 %-11.84%
104.13 %+166.99%
39.00 %-54.98%
86.64 %-52.59%
182.75 %+147.74%
73.77 %-55.26%
164.89 %+108.36%
79.14 %+342.32%
17.89 %-16.60%
21.45 %-63.22%
58.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp is a South Korean pharmaceutical company headquartered in Dangjin. The company manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose; nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions for specific medical cases. It also produces total parenteral nutrition (TPN) products. The company went public on October 27, 2016, with its stock listed on the Korea Exchange under ticker 234080.KS. Its ISIN is KR723080000. The company's website is https://www.jw-lifescience.co.kr/ JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

FCF Conversion Rate (FCF/EBITDA) of JW Life Science is 94.75 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of JW Life Science changed from 91.81 % to 94.75 %, representing a 3.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) JW Life Science since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s JW Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — JW Life Science

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — JW Life Science